Posted on

Fiat Chrysler to investigate actor’s death in car accident

Fiat Chrysler Automobiles N.V. said Monday it is investigating the role played by Anton Yelchin’s 2015 Jeep Grand Cherokee in his death over the weekend. The 27-year old Yelchin died when the car, which was under recall, rolled down his driveway and crushed him against a brick mailbox pillar and security fence. The recall was conducted because of the risk that drivers could exit the vehicle without it remaining in park. In a statement, Fiat Chrysler said it is “in contact with the authorities and is conducting a thorough investigation. It is premature to speculate on the case of this tragedy.” Yelchin, who was born in Russia, was best known for his role as Chekov in the latest reboot of “Star Trek” films, and also appeared on TV’s “Huff,” “ER,” “The Practice,” “Curb Your Enthusiasm” and the 2009 film “Terminator: Salvation.”

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Posted on

2016 Mortgage Refinance Forecast Raised

The projected volume of residential loans expected to be refinanced this year has been increased from last month’s forecast.

Second-quarter mortgage originations, including refinances and purchase-money transactions, are predicted to reach $482 billion.

Volume is then expected to fall to $457 billion during the second quarter and retreat further to $381 billion three months later.

…read more

From:: Financing

Posted on

Mortgage Insurance Guidelines Eased at Radian

Underwriting guidelines that were relaxed by Radian Guaranty Inc. impact loans used for new construction, jumbo mortgages and loans to medical professionals.

On One Underwrite mortgages approved through automated underwriting systems, the minimum FICO score on investment properties has been dropped to 680.

Radian explained that the lower credit score applies to AUS responses of “Approve,” “Accept/Eligible” and “Ineligible” on both purchase financing and refinances.

…read more

From:: Financing

Posted on

Inovio shares up 4.3% after Zika vaccine gets phase 1 trial approval

Inovio Pharmaceuticals Inc. shares rose 4.3% Monday morning after the company received approval to test its Zika vaccine in a phase 1 human trial. GeneOne Life Science is a collaborator on the GLS-5700 vaccine. Interim results from the trial are expected later this year, Inovio president and chief executive officer Dr. J. Joseph Kim said. No vaccines yet exist for Zika virus, though several tests have been developed. With Zika virus posing severe public health risks, particularly in Latin America, companies have scrambled in recent months to develop a vaccine. Earlier this year, the World Health Organization said large-scale trials on a Zika vaccine were at least a year and a half away.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News